Loading...
“Short Course” of Nonpegylated Liposomal Doxorubicin Plus Paclitaxel and Trastuzumb as Primary Systemic Therapy for Operable and Locally-Advanced Breast Cancer: A Phase II Study (PacLiDox 07)
BACKGROUND: Schedules with anthracyclines and taxanes are one of the best options for primary chemotherapy. The addition of trastuzumab showed an impressive percentage of pathological complete responses in Buzdar trial (66.7%). Recently, nonpegylated liposome-encapsulated doxorubicin (NLD) has been...
Na minha lista:
| Udgivet i: | World J Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Elmer Press
2011
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5649686/ https://ncbi.nlm.nih.gov/pubmed/29147255 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4021/wjon393w |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|